Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Operating Income: 2018-2024

Historic Operating Income for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$63.3 million.

  • Silence Therapeutics' Operating Income rose 12.51% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 1.45%. This contributed to the annual value of -$63.3 million for FY2024, which is 1.65% up from last year.
  • Per Silence Therapeutics' latest filing, its Operating Income stood at -$63.3 million for FY2024, which was up 1.65% from -$64.4 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Operating Income peaked at -$46.0 million during FY2020, and registered a low of -$64.4 million during FY2023.
  • Its 3-year average for Operating Income is -$62.9 million, with a median of -$63.3 million in 2024.
  • Per our database at Business Quant, Silence Therapeutics' Operating Income crashed by 58.58% in 2020 and then rose by 3.16% in 2022.
  • Silence Therapeutics' Operating Income (MRY) stood at -$46.0 million in 2020, then tumbled by 36.93% to -$63.0 million in 2021, then increased by 3.16% to -$61.0 million in 2022, then dropped by 5.48% to -$64.4 million in 2023, then increased by 1.65% to -$63.3 million in 2024.
  • Its Operating Income stands at -$63.3 million for FY2024, versus -$64.4 million for FY2023 and -$61.0 million for FY2022.